Clinical Trial Update: Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating PEGPH20 in combination with pembrolizumab for second-line treatment of metastatic pancreatic ductal adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• PEGPH20 (pegylated hyaluronidase)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Pancreatic Cancer Research Team | Conditions: Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer | Phase 2 | Status: UNKNOWN